Dapagliflozin/saxagliptin

Dapagliflozin/saxagliptin is a combination medication used in the treatment of Type 2 diabetes. It contains two active ingredients, dapagliflozin and saxagliptin, which work together to control blood sugar levels in individuals with this condition.

Composition[edit | edit source]

The medication is composed of two active ingredients:

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, leading to a reduction in blood glucose levels.

Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones in the body, which help to regulate insulin production after meals.

Indications[edit | edit source]

Dapagliflozin/saxagliptin is indicated for the treatment of adults with Type 2 diabetes to improve glycemic control when diet and exercise alone does not provide adequate control. It is used when a single agent does not provide adequate control, or when a patient is already being treated with the combination of dapagliflozin and saxagliptin.

Side Effects[edit | edit source]

Like all medications, dapagliflozin/saxagliptin can cause side effects. Common side effects include urinary tract infections, nasopharyngitis, and upper respiratory tract infection. Serious side effects may include hypoglycemia, pancreatitis, and heart failure.

Contraindications[edit | edit source]

Dapagliflozin/saxagliptin is contraindicated in patients with a history of serious hypersensitivity reaction to dapagliflozin or saxagliptin, such as anaphylaxis or angioedema. It is also contraindicated in patients with diabetic ketoacidosis or severe renal impairment.